SCHEMBL67170

SCHEMBL67170

Cc1cncc(N)n1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31749676 1.00
SCHEMBL25429171 0.78 CYP11B1 (0.34)
SCHEMBL110425 0.78
SCHEMBL1604498 0.78
Hydrochloric Acid SCHEMBL31108165 0.76
Ammonia Solution, Strong SCHEMBL28213058 0.76
Hydrochloric Acid SCHEMBL31108166 0.76
SCHEMBL3422108 0.71 CYP11B1 (0.43)
Dimethylamine SCHEMBL19211916 0.71 GRM5 (0.34)
SCHEMBL27934900 0.69 CYP1A2 (0.37)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 412 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119009136-A Pyrazinyl eutectic electrolyte with wide electrochemical stability window, and preparation method and application thereof 中国科学院长春应用化学研究所 2024-11-22 CN claimed
EP-1467976-B1 N-PYRAZINYL-PHENYLSULPHONAMIDES AND THEIR USE IN THE TREATMENT OF CHEMOKINE MEDIATED DISEASES ASTRAZENECA AB (SE) 2011-11-23 EP claimed
WO-2011081310-A3 PEPTIDE MARKER FOR CANCER DIAGNOSIS, AND CANCER DIAGNOSIS METHOD USING SAME 한국기초과학지원연구원 (KR) 2011-10-27 WO claimed
US-20100081670-A1 N-PYRAZINYL-PHENYLSULPHONAMIDES AND THEIR USE IN THE TREATMENT OF CHEMOKINE MEDIATED DISEASES BAXTER ANDREW 2010-04-01 US claimed
US-20070079392-A1 Human G protein-coupled receptors and modulators thereof for the treatment of metabolic-related disorders ARENA PHARMACEUTICALS, INC. (US) 2007-04-05 US claimed
WO-2007035153-A1 NOVEL PROCESS FOR THE PREPARATION OF 6-METHYL-PYRAZIN-2-YLAMINE ASTRAZENECA AB (SE) 2007-03-29 WO claimed
US-20060025423-A1 N-pyrazinyl-phenylsulphonamides and their use in the treatment of chemokine mediated diseases ASTRAZENECA AB (SE) 2006-02-02 US claimed
US-20050004178-A1 Human G protein-coupled receptors and modulators thereof for the treatment of metabolic-related disorders ARENA PHARMACEUTICALS, INC. (US) 2005-01-06 US claimed
US-20040142377-A1 Human G protein-coupled receptors and modulators thereof for the treatment of metabolic-related disorders ARENA PHARMACEUTICALS, INC. (US) 2004-07-22 US claimed
EP-4688148-A1 SELECTIVE RAPAMYCIN ANALOGS AND USES THEREOF Regeneron Pharmaceuticals, Inc. (US) 2026-02-11 EP disclosed
EP-4687881-A2 HETEROARYL ANTIDEGRADANTS Flexsys IP Holdings, LLC (US) 2026-02-11 EP disclosed
WO-2025264724-A1 MPRO INHIBITORS AND USES THEREOF THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2025-12-26 WO disclosed
US-12410183-B2 Sars-cov2 main protease inhibitors GILEAD SCIENCES, INC. (US) 2025-09-09 US disclosed
US-20250236609-A1 VPS34 INHIBITORS AND METHODS OF USE THEREOF DECIPHERA PHARMACEUTICALS, LLC 2025-07-24 US disclosed
WO-2004108692-A1 SULPHONAMIDE COMPOUNDS THAT MODULATE CHEMOKINE RECEPTOR ACTIVITY (CCR4) ASTRAZENECA AB (SE) 2004-12-16 WO disclosed
EP-1467976-A1 N-PYRAZINYL-PHENYLSULPHONAMIDES AND THEIR USE IN THE TREATMENT OF CHEMOKINE MEDIATED DISEASES AstraZeneca AB (SE) 2004-10-20 EP disclosed
US-20040142377-A1 Human G protein-coupled receptors and modulators thereof for the treatment of metabolic-related disorders ARENA PHARMACEUTICALS, INC. (US) 2004-07-22 US disclosed
US-20040005512-A1 Positive-working resist composition FUJI PHOTO FILM CO., LTD. 2004-01-08 US disclosed
EP-1367440-A2 Positive-working resist composition Fuji Photo Film Co., Ltd. (JP) 2003-12-03 EP disclosed
WO-2003059893-A1 N-PYRAZINYL-PHENYLSULPHONAMIDES AND THEIR USE IN THE TREATMENT OF CHEMOKINE MEDIATED DISEASES ASTRAZENECA AB (SE) 2003-07-24 WO disclosed